Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by newdaydawningon Sep 21, 2017 8:17pm

137 Views

Post# 26728646

RE:RE:RE:Good post from investorshub board

I hope your Nov 15 call is right, but if we drag on into December with the next six, we will still have impressive data to present @ AUA conference in May. Will have 6-month efficacy data for the first three and the 3-month response for the remaining six. That should be more than enough evidence to raise eyebrows.

bencro wrote: As long as we have patient #9 treated (high-dose patient #6) by Nov. 15, we will be able to display ALL 6-months cystoscopy data of high-dose patients @AUA Conference in San Francisco (May 18 – 21, 2018).